Stock Events

COSMO Pharmaceuticals N.V. 

€74
0
+€0+0% Today

Statistics

Day High
74
Day Low
72
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
1.18B
P/E Ratio
-
Dividend Yield
2.72%
Dividend
2.01

Upcoming

Dividends

2.72%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
92.35%

Earnings

25JulConfirmed
Q2 2021
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Next
-0.4
0.22
0.85
1.47
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C43.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap300.89B
AbbVie competes in the pharmaceuticals sector, focusing on immunology, oncology, and virology, areas that overlap with COSMO's therapeutic focus.
Johnson & Johnson
JNJ
Mkt Cap357.99B
Johnson & Johnson operates in the pharmaceuticals segment with a broad range of products that could compete with COSMO's offerings in gastrointestinal and dermatology treatments.
Pfizer
PFE
Mkt Cap157.19B
Pfizer is a global biopharmaceutical company with a diverse portfolio that includes products in areas competing with COSMO's focus, such as gastrointestinal diseases.
Merck &
MRK
Mkt Cap331.09B
Merck & Co., Inc. offers innovative health solutions and pharmaceuticals in areas like oncology, which could compete with COSMO's research and product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap85B
Bristol Myers Squibb has a strong presence in biopharmaceuticals, focusing on areas like cancer and immunoscience, potentially competing with COSMO's product lines.
Novartis
NVS
Mkt Cap230.42B
Novartis AG focuses on patented medicines in areas including oncology and dermatology, directly competing with COSMO's research and development efforts.
GSK
GSK
Mkt Cap83.89B
GlaxoSmithKline plc operates in pharmaceuticals with a focus on immunology, potentially competing with COSMO's products in the gastrointestinal and dermatology sectors.
Sanofi
SNY
Mkt Cap119.57B
Sanofi focuses on healthcare solutions in areas like immunology and oncology, which could compete with COSMO Pharmaceuticals' offerings.
Roche
RHHBY
Mkt Cap200.03B
Roche Holding AG specializes in pharmaceuticals and diagnostics with a strong focus on oncology and immunology, competing with COSMO's therapeutic areas.
Astrazeneca
AZN
Mkt Cap244.57B
AstraZeneca PLC operates globally in the pharmaceutical sector, focusing on areas like gastrointestinal diseases, which could compete with COSMO's portfolio.

About

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX " IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Show more...
CEO
Mr. Mauro Severino Ajani
Employees
325
Country
NL
ISIN
NL0011832936
WKN
000A2AJ68

Listings